Core Viewpoint - The stock of Baiaosaitu-B (02315) surged over 15% in early trading, driven by the upcoming IPO on the STAR Market and a recent partnership with Merck for antibody development [1] Group 1: IPO Details - Baiaosaitu plans to raise 1.185 billion yuan through its STAR Market IPO, with funds allocated for early drug development services, antibody drug research, preclinical and clinical research projects, and to supplement working capital [1] - The IPO review is scheduled for September 24, marking a critical milestone for the company [1] Group 2: Partnership with Merck - Earlier this month, Baiaosaitu signed an evaluation agreement with Merck to develop antibody-conjugated lipid delivery solutions for nucleic acid drugs [1] - Under the agreement, Baiaosaitu will provide fully human antibodies developed on its RenMice platform for Merck to assess their feasibility for antibody-conjugated lipid nanoparticle formulations [1] - Merck has been granted exclusive rights to acquire selected antibody assets, while Baiaosaitu is entitled to receive corresponding fee payments, sales shares, and sublicensing royalties [1]

Core Viewpoint - Baiaosaitu-B (02315) has seen a significant stock price increase, attributed to its upcoming IPO on the STAR Market, which is set to raise approximately 1.185 billion yuan for various R&D projects and working capital [1] Group 1: Stock Performance - Baiaosaitu-B's stock rose over 15% in early trading, currently up 11.41% at 27.74 HKD with a trading volume of 12.0264 million HKD [1] Group 2: IPO Details - The IPO is scheduled for review on September 24, with plans to raise 1.185 billion yuan [1] - The funds will be allocated to the construction of a drug early-stage R&D service platform, antibody drug R&D and evaluation projects, preclinical and clinical R&D projects, and to supplement working capital [1] Group 3: Strategic Partnership - Baiaosaitu has signed an evaluation agreement with Merck to develop antibody-conjugated lipid delivery solutions for nucleic acid drugs [1] - Under the agreement, Baiaosaitu will provide fully human antibodies developed on its RenMice® platform for Merck to assess their feasibility for antibody-conjugated lipid nanoparticle formulations [1] - Merck has exclusive rights to acquire selected antibody assets, while Baiaosaitu is entitled to receive corresponding fee payments, sales shares, and sublicensing shares [1]